Trametinib-induced Left Ventricular Dysfunction in a Child With Relapsed Neuroblastoma.

Abstract excerpt

The MEK inhibitor trametinib is globally approved for metastatic melanoma harboring BRAF mutations. There are no reports thus far on its use in children. Exome sequencing on a relapsed tumor sample from an 11-year-old male with progressive, multiply relapsed stage 4 neuroblastoma revealed NRASQ61K mutation. After demonstration of normal cardiac function, he was started on oral trametinib. On day 13 of treatment,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to GTP Phosphohydrolases
• Share to Membrane Proteins